Use of Mesenchymal Stem Cells for the Repair of Articular Cartilage Disorder of Knee Using Intra-articular Injection of Mesenchymal Cells Alone or Mesenchymal Cells With Platelet Lysate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Articular Cartilage Disorder of Knee
- Sponsor
- University of Jordan
- Enrollment
- 13
- Locations
- 1
- Primary Endpoint
- Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Induction of autologous repair chondrogenesis to regenerate injured articular cartilage using bone marrow mesenchymal stem cells (MSCs) after in vitro expansion under restricted culturing conditions.
Detailed Description
Fourteen patients from both genders, age range 40-68, will be enrolled according to strict inclusion and exclusion criteria, divided into two equal groups based upon receiving autologous MSCs alone, or MSCs supported by platelet lysate through percutaneous injection. The patients are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee. The investigators hypothesize that the two groups will give satisfactory clinical outcomes, but the investigators are looking forward to assessing the best product that will activate chondrogenesis and heal cartilaginous injury.
Investigators
Fatima Jamali
Researcher
University of Jordan
Eligibility Criteria
Inclusion Criteria
- •MRI must show moderate/severe articular injury
- •Serum collagen II must be above the normal value.
- •Lesion site: Femoral and Tibial condyles or patella
- •Admission of steroid , NSAID, pain killers must be stopped before 1 month
Exclusion Criteria
- •Lesion size
- •PT and PTT not within normal value
- •Complete blood count ( Hb, PCV, and RBC) not within the normal value
- •HIV and Hepatitis Antigens (B and C) detection
Outcomes
Primary Outcomes
Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.
Time Frame: 12 months
Secondary Outcomes
- Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.(12 months)